The Rosalind Study | Three cohorts, one mission: decoding exceptional Cancer survival across GBM, ES-SCLC and mPDAC

How Cure51 Builds a Global Cancer Research Project Across 50+ Countries

Working hand in hand with patient advocates to advance Pancreatic Cancer Research

A Strategic Partnership to Rethink Pancreatic Cancer Treatment: Cure51 × CRCM × Institut Paoli-Calmettes

Cure51's CEO Nicolas Wolikow: How does AI help advance our Rosalind Study?

Simon Istolainen and Nicolas Wolikow: The History of Cure51 and the Vision Behind a New Model in Oncology

Rosalind Study Milestone: 115+ Centers Join Cure51’s International Oncology Network

Cure51's CEO Nicolas Wolikow: "Reverse-Engineering the Cure to Cancer: A New Paradigm in Oncology Research"

WE’RE THRILLED TO WELCOME ASHLEY LAKNER, PHD, AS OUR NEW CHIEF SCIENTIFIC OFFICER (CSO)!

Cure51's CEO Nicolas Wolikow and Yann Bizien addressing rising rates of early-onset Cancer in France

What is a Clinical Trial in Cancer Care? A Complete Guide for Patients

Discover how Elio, Cure51’s multi-agent AI system, connects clinical, multi-omics and research data to accelerate Cancer discovery and innovation.

CURE51 achieves ISO 27001 & HDS certifications for secure health data hosting GDPR-compliant platform for pharmaceutical & oncology research

Happy New Year 2026! Reflecting on Cure51’s Cancer Research Progress & the Rosalind Study

Rosalind Study Launches in Dubai in collaboration with Mediclinic Middle East City Hospital and Dr. Shaheenah Dawood to Advance Cancer Research

Despite pessimistic diagnoses, some patients live for many years, or are even cured. Cure51 studies these extraordinary cases to eradicate Cancer.

How are TechBio companies redefining the future of drug discovery and development?